Impacto do tratamento com inibidor de SGLT2 em pacientes cardiorrenais

• Autores: Ana Carolina Correia Cruz, Luana Carla dos Santos, Thiago Augusto Rochetti Bezerra
• Localización: Cuadernos de Educación y Desarrollo, ISSN-e 1989-4155, Vol. 16, Nº. Extra 2, 2024
• Idioma: inglés
• DOI: 10.55905/cuadv16n2-ed.esp.272
• Enlaces
  • Texto completo
• Resumen

  • O co-transportador de sódio-glicose 2 faz a reabsorção da glicose filtrada a partir dos glomérulos renais, promovendo seu retorno ao sangue. Desta forma, os inibidores de SGLT2 (iSGLT2) atuam como hipoglicemiantes, mostrando-se importante o estudo das consequências geradas por tal efeito no organismo.

• Referencias bibliográficas
  • LI, Ning et al. Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: A meta-analysis. Plos One, v.17, p.1,...
  • QIU, Mei et al. Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors....
  • WEI, Wen et al. Sodium glucose cotransporter type 2 inhibitors improve cardiorenal outcome of patients with coronary artery disease: a meta-analysis....
  • YAMADA, Takayuki et al. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes...
  • ZHAO, Li-Min et al. Gliflozins for the prevention of stroke in diabetes and cardiorenal diseases: a metaanalysis of cardiovascular outcome...